Filter
5768
Filtered Results: 5768
Text search:
COVID-19
Featured
Recommendations
715
New Publications
55
Language
Document type
Guidelines
1415
Studies & Reports
1366
Fact sheets
716
Infographics
402
Strategic & Response Plan
355
Manuals
348
Resource Platforms
264
Situation Updates
246
Videos
211
Training Material
125
No document type
122
Online Courses
95
Brochures
87
App
10
Dashboards/Maps
6
Countries / Regions
Global
367
Germany
282
Russia
257
Latin America and the Carribbean
227
Brazil
207
India
172
Middle East and North Africa
150
West and Central Africa
133
Africa
130
Syria
125
South Africa
125
Ukraine
112
East and Southern Africa
112
Mozambique
108
Eastern Europe and Central Asia
105
Yemen
96
Colombia
89
Western and Central Europe
88
Angola
84
Argentina
65
South Sudan
64
Congo, Democratic Republic of
63
Kenya
63
Peru
55
Venezuela
53
Spain
51
Guinea-Bissau
47
South–East Asia Region
47
Ecuador
44
Haiti
42
Bangladesh
41
Chile
41
Eastern Europe
40
Ethiopia
39
Nigeria
38
Burkina Faso
37
Italy
30
Mali
29
Niger
29
Bolivia
28
Myanmar / Burma
27
Paraguay
27
Senegal
26
Somalia
26
Malawi
25
Portugal
25
Afghanistan
23
Lebanon
23
Indonesia
22
Sudan
22
El Salvador
22
Côte d’Ivoire / Ivory Coast
21
China
21
Western Pacific Region
21
Canada
21
Uganda
20
Philippines
19
Central African Republic
19
Mexico
19
Singapore
18
Pakistan
17
Vietnam
17
Ghana
16
Chad
16
Cameroon
15
Zambia
14
Turkey
14
Iraq
13
France
13
United Kingdom
13
Jordan
12
Thailand
12
Madagascar
12
Rwanda
11
Malaysia
11
Honduras
11
Kazakhstan
11
Guinea
10
Liberia
10
Nepal
10
Tanzania
10
Benin
10
Congo-Brazzaville
10
Iran
10
Sierra Leone
9
Saudi Arabia
9
Zimbabwe
9
Cambodia
9
Burundi
9
Libya
9
Guatemala
9
Luxembourg
9
Palestine
9
Moldova
9
Egypt
8
Laos
8
Tajikistan
8
Tunisia
8
Algeria
8
USA
7
Namibia
7
Austria
7
Switzerland
7
Nicaragua
7
Asia
7
Djibouti
7
North America
7
Togo
6
Mauritania
6
Ireland
6
Dominican Republic
6
Kyrgyzstan
6
Uruguay
6
Morocco
5
Eswatini/ Swaziland
5
Hungary
5
Greece
5
North Korea
5
Uzbekistan
5
Georgia
5
Jamaica
5
South Korea
5
Belarus
5
Lesotho
4
Sri Lanka
4
Japan
4
Papua New Guinea
3
Serbia
3
Cuba
3
Poland
3
Turkmenistan
3
Belgium
3
North Macedonia
2
Botswana
2
Cape Verde
2
Armenia
2
Timor Leste/ East Timor
2
Bulgaria
2
Romania
2
Gabon
2
Denmark
2
Mauritius
2
French Guyana
2
Israel
2
Gambia
1
Vanuatu
1
Fiji
1
Solomon Islands
1
Bhutan
1
Mongolia
1
Southern Africa
1
Qatar
1
Slovakia
1
Australia
1
Norway
1
Morocco
1
Authors & Publishers
Publication Years
Category
Countries
2723
Public Health
176
Key Resources
168
Women & Child Health
161
Clinical Guidelines
148
Capacity Building
75
Pharmacy & Technologies
41
Annual Report MEDBOX
2
Toolboxes
COVID-19
3782
Refugee
244
Planetary Health
228
Conflict
159
Mental Health
128
Caregiver
127
HIV
99
Health Financing Toolbox
80
TB
79
NCDs
79
Rapid Response
76
Global Health Education
72
AMR
53
NTDs
49
Natural Hazards
39
Pharmacy
29
Disability
27
Ebola
21
Cholera
8
Polio
8
Social Ethics
6
Specific Hazards
5
Zika
4
Health Financing
1
The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows:
National action plan key activities, prioritized for the current context and the current ...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-.... This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
A country’s ability to manage a crisis depends on its level of resilience. Efforts are made to clarify the concept of health system resilience, but its operationalisation remains little studied. In the present research, we described the capacity of the local healthcare system in the Islamic Republ...
The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financ...
This article analyzes the impact of the COVID-19 pandemic on foreign aid. Using examples from Canadian foreign aid, it argues that, despite the terrible toll it is exacting, the crisis has accelerat...
This article analyzes the impact of the COVID-19 pandemic on foreign aid.
Does Diabetes make someone vulnerable to getting COVID-19:
People with Diabetes are not more likely to get the virus compared to the general public.
However, if they contact ...-19, people with diabetes are more likely to have serious complications and become seriously ill from COVID-19, than those who do not have diabetes.
If a person with diabetes gets COVID 19, he is more vulnerable to severe form of COVID-19 and is more likely to die than those without diabetes.
ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19? People with diabetes are more likely to become seriously ill from COVID-..., than those who do not have diabetes. Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.
ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19?
• People with diabetes are more likely to become seriously ill from COVID-..., than those who do not have diabetes.
• Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.
ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19?
• People with diabetes are more likely to become seriously ill from COVID-..., than those who do not have diabetes.
• Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.
In 2018 the Astana Declaration reaffirmed a global commitment to PHC as a cornerstone of sustainable health systems for accelerated progress on universal health coverage (UHC) (1). The vision for PHC in the 21st century is for a wholeof-government and whole-of-society approach to health that combine...
Action Plan for Implementation of Recommendations from the Evaluation of PAHO's Response to COVID-19
An external team evaluated PAHO’s response to COVID-19 to provide an independent assessment of the Pan American Sanitary Bureau’s (PASB) performance regarding preparedness for and response to th...
The "Stories from the field" document by the WHO Regional Office for the Eastern Mediterranean shares effective strategies from the Eastern Mediterranean Region for addressing noncommunicable diseases (NCDs) and mental health challenges, particularly during the ...-19 pandemic. It highlights regional success stories in mitigating NCDs and mental health conditions through innovative, country-specific interventions. The report emphasizes multisectoral collaboration, community engagement, and resilience in public health responses. It aims to inspire further action and knowledge-sharing to enhance health outcomes in challenging settings across the region.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the ...-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
"Tackling Noncommunicable Diseases (NCDs), risk factors and mental health during the time of COVID-19" is a series of high-level strategic discussions on transforming the approach to noncommunicable...
As Uganda builds back from the COVID-19 shock, the Ugandan government is strengthening its commitment to a more gender-inclusive and sustainable economy. This report supports these efforts by descri...
The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navi...
Basic information about the virus, symptoms, prevention and transmission.
Si tienes tos, puedes tener una enfermedad respiratoria:
Puede ser COVID-19, si es de aparición rápida, acompañada de tos seca, malestar general, fiebre y dificultad para respirar.
Puede se...
Los gobiernos de todo el mundo están aplicando rápidamente medidas para contener la propagación de COVID-19 y proteger a sus ciudadanos. Muchos gobiernos están estableciendo centros de cuarenten...
